natgillin/translations-raw huggingface dataset:
The event rate for locally read BPAR during the 360-day study was 1.2% in the Envarsus group (N=162) post conversion from Prograf at a dose ratio of 1:0.7 (mg:mg) and 1.2% in the group maintained on Prograf (N=162). 
Stopnja dogodkov za lokalno določeno BPAR med 360-dnevno študijo je bila 1,2 % v skupini z zdravilom Envarsus (N = 162) po prehodu z zdravila Prograf z razmerjem odmerkov 1:0,7 (mg:mg) in 1,2 % v skupini, ki je ostala na zdravilu Prograf
When substances with a potential for interaction (see section 4.5), particularly strong inhibitors of CYP3A4 (such as telaprevir, boceprevir, ritonavir, ketoconazole, voriconazole, itraconazole, telithromycin, or clarithromycin) or inducers of CYP3A4 (such as rifampicin or rifabutin), are being combined with tacrolimus, tacrolimus blood levels should be monitored to adjust the tacrolimus dose as appropriate in order to maintain similar tacrolimus exposure. 
Pri kombinirani uporabi učinkovin, pri katerih obstaja možnost za medsebojno delovanje (glejte poglavje 4.5), zlasti močnih zaviralcev CYP3A4 (kot so telaprevir, bokeprevir, ritonavir, ketokonazol, vorikonazol, itrakonazol, telitromicin ali klaritromicin) ali induktorji CYP3A4 (kot sta rifampicin ali rifabutin) skupaj s takrolimusom, je treba nadzirati ravni takrolimusa v krvi in ustrezno prilagajati odmerek takrolimusa, da se vzdržuje podobna izpostavljenost takrolimusu.
- if you have diarrhoea for more than one day. 
- če imate ali ste kdaj prej imeli težave z jetri, - če imate več kot en dan drisko,
Lansoprazol and ciclosporin may potentially inhibit CYP3A4-mediated metabolism of tacrolimus and, thereby, increase tacrolimus whole blood concentrations. 
Lansoprazol in ciklosporin lahko potencialno zavirata presnovo takrolimusa s CYP3A4 in tako zvišata koncentracije takrolimusa v polni krvi.
Each tablet contains 41.7 mg lactose monohydrate. 
Ena tableta vsebuje 41,7 mg laktoze monohidrata.
Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.4 and 4.8). 
Bolniki naj ves čas ohranjajo eno farmacevtsko obliko takrolimusa z ustreznim dnevnim režimom odmerjanja; spremembe v farmacevtski obliki ali režimu naj se izvajajo le pod skrbnim nadzorom specialista za presaditve (glejte poglavji 4.4 in 4.8).
Reproductive system and breast disorders dysmenorrhoea and uterine bleeding 
Motnje reprodukcije in dojk dismenoreja in krvavitev iz maternice
Effect of other medicinal products on the metabolism of tacrolimus 
Vpliv drugih zdravil na presnovo takrolimusa
The relationship between tacrolimus trough levels (C24) and systemic exposure (AUC0-24) for Envarsus is similar to that of immediate-release tacrolimus. 
Razmerje med najnižjimi vrednostmi takrolimusa (C24) in povprečni sistemski izpostavljenosti (AUC0-24) za zdravilo Envarsus je podobno kot pri takrolimusu s takojšnjim sproščanjem.
It is strongly recommended to closely monitor tacrolimus blood levels, as well as renal function and other undesirable effects, whenever substances which have the potential to alter CYP3A4 metabolism or otherwise influence tacrolimus blood levels are used concomitantly, and to interrupt or adjust the tacrolimus dose as appropriate in order to maintain similar tacrolimus exposure (see sections 4.2 and 
Zato je koncentracijo takrolimusa v krvi ter delovanje ledvic in ostalih neželenih učinkov priporočljivo nadzirati, kadar koli sočasno uporabljate učinkovine, ki lahko spremenijo presnovo CYP3A ali kako drugače vplivajo na koncentracijo takrolimusa v krvi in odmerek takrolimusa ustrezno prilagoditi, da bi izpostavljenost takrolimusu ohranili približno enako (glejte poglavji 4.2 in 4.4).
Psychiatric disorders insomnia confusion and disorientation, depression, anxiety symptoms, hallucination, mental disorders, depressed mood, mood disorders and disturbances, nightmare psychotic disorder 
Psihiatrične motnje nespečnost zmedenost in dezorientiranost, depresija, simptomi anksioznosti, halucinacije, duševne motnje, potrtost, motnje razpoloženja, nočne more psihotična motnja
Pack sizes of 30, 60 and 90 prolonged-release tablets. 
Velikosti pakiranja po 30, 60 in 90 tablet s podaljšanim sproščanjem.
Clinical data suggest that the pharmacokinetics of statins are largely unaltered by the co-administration of tacrolimus. 
Klinični podatki kažejo, da sočasna uporaba takrolimusa v glavnem ne spremeni farmakokinetike statinov.
Patients treated with immunosuppressants, including Envarsus, are at increased risk for infections including opportunistic infections (bacterial, fungal, viral and protozoal) such as BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML). 
Pri bolnikih, zdravljenih z imunosupresivi, vključno z zdravilom Envarsus, je večje tveganje za okužbe, vključno z oportunističnimi okužbami (bakterijske, glivične, virusne in protozojske), kot sta nefropatija, povezana z virusom BK, in progresivna multifokalna levkoencefalopatija (PML),
Herbal preparations containing St. John's Wort (Hypericum perforatum) should be avoided when taking tacrolimus due to the risk of interactions that lead to a decrease in both blood concentrations and the therapeutic effect of tacrolimus (see section 4.5). 
Med jemanjem takrolimusa bolniki ne smejo uporabljati zeliščnih pripravkov, ki vsebujejo šentjanževko (Hypericum perforatum) zaradi nevarnosti za medsebojno delovanje, ki zmanjša koncentracijo takrolimusa v krvi in oslabi njegov klinični učinek (glejte poglavje 4.5).
Increased doses of tacrolimus, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes. 
Za obvladanje zavrnitvenih epizod so uporabljali večje odmerke takrolimusa, dodatno zdravljenje s kortikosteroidi in uvedbo kratkih ciklusov mono-/poliklonskih protiteles.
30 prolonged-release tablets 60 prolonged-release tablets 90 prolonged-release tablets 
30 tablet s podaljšanim sproščanjem 60 tablet s podaljšanim sproščanjem 90 tablet s podaljšanim sproščanjem
For treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients clinical studies are not yet available for the prolonged-release formulation Envarsus. 
Za zdravljenje zavrnitve alogenskega presadka, odporne na zdravljenje z drugimi imunosupresivi, pri odraslih bolnikih klinične študije za farmacevtsko obliko s podaljšanim sproščanjem Envarsus še niso na voljo.
In current clinical practice, whole blood levels are monitored using immunoassay methods. 
V klinični praksi se za nadziranje koncentracije v polni krvi trenutno uporabljajo metode imunskega preskusa.
Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.2 and 4.8). 
Bolniki naj ves čas ohranjajo eno farmacevtsko obliko takrolimusa z ustreznim dnevnim režimom odmerjanja; spremembe v farmacevtski obliki ali režimu odmerjanja naj se izvajajo le pod skrbnim nadzorom specialista za presaditve (glejte poglavji 4.2 in 4.8).
You will need to take Envarsus every day as long as you need immunosuppression to prevent rejection of your transplanted organ. 
Kako dolgo moram jemati tablete zdravila Envarsus Zdravilo Envarsus boste morali jemati vsak dan, dokler potrebujete imunosupresijo zaradi preprečevanja zavrnitve presajenega organa.
The educational material for Healthcare Professionals should include information on the following key elements: - The authorised indications - The need for prescribing and dispensing with attention to pharmaceutical form (prolonged-release) and posology (once daily administration). 
Izobraževalno gradivo za zdravstvene delavce mora vsebovati informacije o naslednjih ključnih elementih: - odobrene indikacije - Pri predpisovanju in izdajanju zdravila je potrebna pozornost zaradi farmacevtske oblike
Caution should be exercised in patients with diagnosed or suspected Congenital Long QT Syndrome. 
Previdnost je potrebna pri bolnikih, ki imajo ugotovljen prirojeni sindrom podaljšanega QT intervala, ali pa obstaja sum, da imajo ta sindrom.
Possible interactions with other active substances known to have high affinity for plasma proteins should be considered (e.g. NSAIDs, oral anticoagulants or oral antidiabetics). 
Upoštevati je treba možnost medsebojnega delovanja z učinkovinami, ki imajo veliko afiniteto za beljakovine v plazmi (npr. nesteroidna protivnetna zdravila, peroralni antikoagulanti ali peroralni antidiabetiki).
Care should be taken when converting patients from ciclosporin-based to tacrolimus-based therapy (see sections 4.4 and 4.5). 
Pri prehodu bolnikov z zdravljenja na osnovi ciklosporina na zdravljenje na osnovi takrolimusa je potrebna previdnost (glejte poglavji 4.4 in 4.5).
In all, there appears to be no significant difference in the pattern of adverse events suspected to be causally related to study drug between once daily Envarsus and tacrolimus immediate-release capsules (Prograf). 
Kaže, da ni značilne razlike v vzorcu neželenih učinkov, ki so domnevno povezane s študijskim zdravilom, med zdravilom Envarsus enkrat na dan in kapsulami takrolimusa s takojšnjim sproščanjem (zdravilo Prograf).
The event rate for centrally read, biopsy-confirmed acute rejection (BPAR) during the 360-day study was 13.1% in the Envarsus group (N=268) and 13.5% in the Prograf group (N=275). 
Stopnja dogodkov za centralno določeno, z biopsijo potrjeno akutno zavrnitvijo (BPAR - biopsy-confirmed acute rejection) med 360-dnevno študijo je bila 13,1 % za skupino z zdravilom Envarsus (N = 268) in 13,5 % za skupino z zdravilom Prograf (N = 275).
The half-life of ciclosporin is prolonged when tacrolimus is given concomitantly. 
Pri sočasni uporabi takrolimusa se razpolovni čas ciklosporina podaljša.
In healthy subjects, the average total body clearance estimated from whole blood concentrations was 2.25 L/h. 
ocenjen iz koncentracij polne krvi, 2,25 l/h.
For prophylaxis of transplant rejection in adult heart, lung, pancreas, or intestine allograft recipients clinical data are not yet available for Envarsus. 
Za preprečevanje zavrnitve presadka pri odraslih po alogenski presaditvi srca, pljuč, trebušne slinavke ali črevesja klinični podatki za farmacevtsko obliko s podaljšanim sproščanjem Envarsus še niso na voljo.
The tablets should be swallowed whole with fluid (preferably water) immediately following removal from the blister. 
Bolnik mora tablete takoj po odstranitvi pretisnega omota pogoltniti cele skupaj s tekočino (najbolje z vodo).
Human data show that tacrolimus crosses the placenta. 
Podatki pri ljudeh kažejo, da takrolimus prehaja skozi placento.
Envarsus blood levels can be affected by other medicines you take, and blood levels of other medicines can be affected by taking Envarsus, which may require interruption, an increase or a decrease in Envarsus dose. 
Druga zdravila, ki jih jemljete, lahko vplivajo na koncentracijo zdravila Envarsus v krvi, pa tudi jemanje zdravila Envarsus lahko vpliva na koncentracijo drugih zdravil v krvi, zato bo morda treba odmerek zdravila Envarsus povečati ali zmanjšati.
Results from clinical studies performed with once-daily tacrolimus 
Rezultati kliničnih študij, opravljenih s takrolimusom enkrat na dan Presaditev ledvic
Concomitant use of substances known to inhibit or induce CYP3A4 may affect the metabolism of tacrolimus and thereby increase or decrease tacrolimus blood levels. 
Sočasna uporaba zdravil ali zeliščnih pripravkov, ki zavirajo ali inducirajo CYP3A4, lahko vpliva na presnovo takrolimusa in zviša ali zniža njegovo koncentracijo v krvi.
Treatment emergent fatal adverse events occurred in 1.2% of Envarsus patients and 0.6% of Prograf patients. 
Smrtni dogodki, povezani z zdravljenjem, so se pojavili pri 1,2 % bolnikov, zdravljenih z zdravilom Envarsus, in pri 0,6 % bolnikov, zdravljenih z zdravilom Prograf.
cysts and polyps) Patients receiving immunosuppressive therapy are at increased risk of developing malignancies. 
Bolnike, ki prejemajo imunosupresive, bolj ogroža pojav malignomov.
Do not take a double dose to make up for a forgotten tablet. 
Če ste pozabili vzeti zdravilo Envarsus Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnjo tableto.
3 blisters are packed together in an aluminium foil wrapper containing a desiccant. 
3 pretisni omoti so pakirani skupaj v ovitku iz aluminijaste folije s sušilnim sredstvom.
Patients are also at an increased risk of infections with viral hepatitis (e.g. hepatitis B and C reactivation and de novo infection, as well as hepatitis E, which may become chronic). 
(na primer reaktivacija okužbe s hepatitisom B ali C ali prva okužba z njima, kot tudi s hepatitisom E, ki lahko postane kronična).
Dosing should primarily be based on clinical assessments of rejection and tolerability in each individual patient aided by whole blood tacrolimus trough level monitoring. 
Odmerjanje mora temeljiti predvsem na klinični oceni zavrnitve in prenašanja pri vsakem bolniku posebej s pomočjo spremljanja najnižje koncentracije takrolimusa v krvi.
Tacrolimus therapy requires careful monitoring by adequately qualified and equipped personnel. 
Zdravilo Envarsus je peroralna farmacevtska oblika takrolimusa, ki se ga jemlje enkrat na dan. Zdravljenje s takrolimusom mora natančno nadzorovati ustrezno usposobljeno in opremljeno osebje.
In plasma, tacrolimus is highly bound (>98.8%) to plasma proteins, mainly to serum albumin and α-1-acid glycoprotein. 
vezan na plazemske beljakovine, predvsem na serumski albumin in α-1-kisli glikoprotein.
Therefore, Envarsus should generally be taken on an empty stomach to achieve maximal absorption. 
Zato je treba za dosego največje absorpcije zdravilo Envarsus praviloma jemati na prazen želodec.
ANNEX II A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z
Elderly patients (> 65 years) There is no evidence currently available to indicate that dose should be adjusted in elderly patients. 
Trenutno ni dokazov, da bi bila pri starejših bolnikih potrebna prilagoditev odmerjanja.
Some cases have reported resolution on switching to alternative immunosuppression. 
V nekaterih primerih so poročali o prenehanju teh motenj prehodu na drugo imunosupresivno zdravljenje.
Allergic and anaphylactoid reactions have been observed in patients receiving tacrolimus (see section 4.4). 
Pri bolnikih, ki so dobivali takrolimus, so opisane alergijske in anafilaktoidne reakcije (glejte poglavje 4.4).
Treatment-emergent fatal adverse events occurred in 1.8% of Envarsus patients and 2.5% of Prograf patients. 
Smrtni dogodki, povezani z zdravljenjem, so se pojavili pri 1,8 % bolnikov, zdravljenih z zdravilom Envarsus, in pri 2,5 % bolnikov, zdravljenih z zdravilom Prograf.
In clinical studies patients converted from twice daily Prograf were converted to Envarsus at 1:0.85 (mg:mg). 
V kliničnih študijah so pri prehodu bolnikov z zdravila Prograf dvakrat na dan na zdravilo Envarsus uporabili razmerje 1:0,85 (mg:mg).
Envarsus therapy should commence at a dose of 0.17 mg/kg/day administered once daily in the morning. 
Profilaksa zavrnitve presajene ledvice Zdravljenje z zdravilom Envarsus je treba začeti z odmerkom 0,17 mg/kg/dan enkrat na dan zjutraj.
- The active substance is tacrolimus. 
- Učinkovina je takrolimus.
Factors such as low haematocrit and protein levels, which result in an increase in the unbound fraction of tacrolimus, or corticosteroid-induced increased metabolism, are considered to be responsible for the higher clearance rates observed following transplantation. 
Velja, da so za višje stopnje očistka, ki so jih opazili po presaditvi, odgovorni dejavniki, kot so nizke ravni hematokrita in beljakovin, ki povzročijo povečanje nevezanih frakcij takrolimusa ali večjo presnovo zaradi kortikosteroida.
Blood trough levels of tacrolimus should also be closely monitored following conversion from tacrolimus products, dose adjustments, changes in the immunosuppressive regimen, or co-administration of substances which may alter tacrolimus whole blood concentrations (see section 4.5). 
Najnižje koncentracije takrolimusa v krvi je treba nadzirati tudi po prehodu z zdravila s takrolimusom, prilagoditvi odmerka, spremembah imunosupresivnega režima ali sočasni uporabi učinkovin, ki lahko spremenijo koncentracije takrolimusa v polni krvi
How long should I take the Envarsus tablets 
Kako moram jemati tablete zdravila Envarsus
Inadvertent, unintentional, or unsupervised switching of immediate- or prolonged-release formulations of tacrolimus is unsafe. 
Nepazljiva, nenamerna ali nenadzorovana zamenjava farmacevtskih oblik takrolimusa s takojšnjim ali podaljšanim sproščanjem ni varna.
Therefore, you may be more prone to infections while you are taking Envarsus. 
Morda boste zaradi tega med jemanjem zdravila Envarsus bolj nagnjeni k okužbam.
There is a risk for premature delivery (<37 week) (incidence of 66 of 123 births, i.e. 53.7%; however, data showed that the majority of the newborns had normal birth weight for their gestational age) as well as for hyperkalaemia in the newborn (incidence 8 of 111 neonates, i.e. 7.2 %) which, however normalises spontaneously. 
vendar pa podatki kažejo, da je imela večina novorojenčkov normalno telesno maso za svojo gestacijsko starost) ter za hiperkaliemijo pri novorojenčkih (incidenca 8 od 111 novorojenčkov, tj.
Patients treated with tacrolimus have been reported to develop Epstein-Barr Virus (EBV)-associated lymphoproliferative disorders (see section 4.8). 
Pri bolnikih, ki so se zdravili s takrolimusom, so poročali o pojavu z Epstein-Barr virusom (EBV)
Envarsus contains the active substance tacrolimus presented in a prolonged release formulation. 
Zdravilo Envarsus vsebuje učinkovino takrolimus v farmacevtski obliki s podaljšanim sproščanjem.
You should limit your exposure to the sun and UV (ultraviolet) light whilst taking Envarsus. 
Med jemanjem zdravila Envarsus morate omejiti izpostavljenost sončni svetlobi in ultravijoličnim žarkom.
How to store Envarsus 
Kako jemati zdravilo Envarsus
Nervous system disorders headache, tremor nervous system disorders seizures, disturbances in consciousness, peripheral neuropathies, dizziness, paraesthesias and dysaesthesias, writing impaired encephalopathy, central nervous system haemorrhages and cerebrovascular accidents, coma, speech and language ab-normalities, paralysis and paresis, amnesia hypertonia myasthenia 
motnje zavesti, periferne nevropatije, omotica, parestezije in dizestezije, motnje pri pisanju encefalopatija, krvavitve v osrednje živčevje in cerebrovaskularni incidenti, koma, motnje govora in izražanja, paraliza in pareza, amnezija hipertonija miastenija
Envarsus therapy should commence at a dose of 0.11-0.13 mg/kg/day administered once daily in the morning. 
Profilaksa zavrnitve presajenih jeter Zdravljenje z zdravilom Envarsus je treba začeti z odmerkom 0,11 do 0,13 mg/kg/dan enkrat na dan zjutraj.
A negative effect of tacrolimus on male fertility in the form of reduced sperm count and motility was observed in rats (see section 5.3). 
Pri podganah je takrolimus negativno učinkoval na plodnost samcev; kazal se je z zmanjšanjem števila in gibljivosti spermijev (glejte poglavje 5.3).
Ear and labyrinth disorders tinnitus hypoacusis deafness neurosensory hearing impaired 
vključno z motnjami labirinta tinitus hipoakuzija nevrosenzo rična naglušnost okvara sluha
As in kidney transplant recipients, there appears to be no meaningful difference in the pattern of suspected adverse drug reactions between once daily Envarsus and tacrolimus immediate-release capsules (Prograf). 
pri prejemnikih presajene ledvice ni značilne razlike v vzorcu neželenih učinkov, ki so domnevno povezani z zdravilom Envarsus enkrat na dan in kapsulami takrolimusa s takojšnjim sproščanjem (zdravilo Prograf).
Allograft transplant patients maintained on twice daily Prograf (immediate-release) or Advagraf (once daily) dosing requiring conversion to once daily Envarsus should be converted on a 1:0.7 (mg:mg) 
Po alogenski presaditvi je treba pri bolnikih, pri katerih se vzdržuje odmerjanje zdravila Prograf dvakrat na dan (takojšnje sproščanje) ali zdravila Advagraf (enkrat na dan), in pri katerih je potreben prehod na zdravilo Envarsus enkrat na dan, prehod opraviti na osnovi skupnega dnevnega odmerka 1:0,7 (mg:mg), vzdrževalni odmerek zdravila Envarsus pa naj bo zato 30 % manjši od odmerka zdravila Prograf ali Advagraf.
Metabolism and nutrition disorders diabetes mellitus, hyperglycaemic conditions, hyperkalaemia anorexia, metabolic acidoses, other electrolyte abnormalities, hyponatraemia, fluid overload, hyperuricaemia, hypomagnesaemia, hypokalaemia, hypocalcemia, appetite decreased, hypercholesterolaemia, hyperlipidaemia, hypertriglyceridaemia, hypophosphateaemia dehydration, hypoglycaemia, hypoproteinaemia, hyperphosphataemia 
hiperurikemija, hipomagneziemija, hipokaliemija, hipokalciemija, zmanjšanje apetita, hiperholesterolemija, hiperlipidemija, hipertrigliceridemija, hipofosfatemija dehidracija, hipoglikemija, hipoproteinemija, hiperfosfatemija
As tacrolimus is a substance with low clearance, adjustments to the dose regimen may take several days before steady state is achieved. 
Ker je očistek takrolimusa majhen, lahko prilagajanje odmerka za vzpostavitev stanja dinamičnega ravnovesja traja več dni.
Medication errors, including inadvertent, unintentional or unsupervised substitution of immediate- or prolonged-release tacrolimus formulations, have been observed. 
Opazili so napake pri uporabi zdravila, vključno z nepazljivo, nenamerno ali nenadzorovano zamenjavo farmacevtskih oblik takrolimusa s takojšnjim ali podaljšanim sproščanjem.
From time to time, your doctor may need to do blood, urine, heart, or eye tests, to set the right dose of Envarsus. 
srca ali oči, da bo določil pravilni odmerek zdravila Envarsus.
Cardiac disorders ischaemic coronary artery disorders, tachycardia heart failures, ventricular arrhythmias and cardiac arrest, supraventricular arrhythmias, cardiomyopathies, ventricular hypertrophy, palpitations pericardial effusion 
ventrikularne aritmije in zastoji srca, supraventrikularne aritmije, kardiomiopatije, ventrikularna hipertrofija, palpitacije perikardialni izliv
Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including tacrolimus. 
Pri bolnikih, zdravljenih z imunosupresivi, vključno s takrolimusom, so poročali o primerih nefropatije, povezane z virusom BK, kot tudi progresivne multifokalne levkoencefalopatije (PML), povezane z virusom JC.
Concurrent use of tacrolimus with medicinal products known to have nephrotoxic or neurotoxic effects may increase these effects (e.g. aminoglycosides, gyrase inhibitors, vancomycin, cotrimoxazole, NSAIDs, ganciclovir, or aciclovir). 
Te učinke lahko poveča sočasna uporaba takrolimusa in zdravil z nefrotoksičnimi ali nevrotoksičnimi učinki (kot so aminoglikozidi, zaviralci giraze, vankomicin, kotrimoksazol, nesteroidni antirevmatiki,
Tacrolimus is a low-clearance substance. 
Izločanje Takrolimus je učinkovina z nizkim očistkom.
The treatment failure rate using the same composite end-point with centrally read BPAR was 1.9% in the Envarsus group and 3.7% in the Prograf group (95% confidence interval [6.51%, 2.31%]). 
1,9 % v skupini z zdravilom Envarsus in 3,7 % v skupini z zdravilom Prograf (95-odstotni interval zaupanja [-6,51 %; 2,31 %]).
Envarsus contains lactose 
Zdravilo Envarsus vsebuje laktozo